a drug which acts as a 5ht1a agonist, proposed for use in the treatment of several neurodegenerative conditions including alzheimer's disease.
one of the new agents that was discussed at asco this year was a drug that sanofi-aventis is developing to assist in the management of the neurotoxicity that we see with oxaliplatin. this is an experimental drug, xaliproden, i think there [are] two pronunciations for it. and what we have seen in this trial, which, clearly, it's not the panacea that we want it to be, but we see where we can shift some of the grade 3 toxicities more into grade 2 [i.e., lessen the severity somewhat]. everydayhealth.com